Agios Pharmaceuticals, Inc.
AGIO · Nasdaq · USD · Market cap $1.8B · 539 employees
Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States.
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price27.60 USD at the 20 Nov 2026 close
- Our value readUndervalued vs our fair value, as of 20 Nov 2026
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans to puts (put/call 2.13)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: $32.00 to $59.36, base estimate $43.00 (screen dated 2026-11-20).
- Trend Markup
- Insiders insiders sold, $296,470, latest filing 2026-10-26
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 2.13, read 2026-11-19
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Agios Pharmaceuticals, Inc. holds its Markup at $27.60. The statistical read favours the sellers, held for 10 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 10 days |
| Price at the screen | $27.60 |
| Valuation | N/A trailing · -9.36 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 0.62 |
Five Screens: AGIO's Results
FAIL. Revenue purity
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 3.10% | Below 33% | Pass |
| Interest-bearing cash | 23.90% | Below 33% | Pass |
| Receivables | 7.69% | Below 49% | Pass |
| Revenue purity | 100.00% | Below 5% | Fail |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Agios Pharmaceuticals, clears the business-activity screen, and its debt is inside the line. Where it falls short is income purity: around 100% of its income right now is interest earned on a large cash position, against a roughly 5% ceiling, so it does not pass. That reflects what it earns today, not the business itself, and it could clear the screen if its operating revenue grows and the interest share falls.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when AGIO's ethical verdict changes
Today AGIO does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Our analysis reads Undervalued to fair value, as of 20 Nov 2026: it trades at roughly a 36% discount to our $43.00 fair value, 330.00% revenue growth.
USD, 2026-11-20 screen. A 35.8% under base.
Street: 9 covering, consensus Buy. Average target +56%.
New Enzyme Drug Drives Biotech Revenue Explosion
Picture a patient finally getting a pill that switches a faulty enzyme back on in rare blood disorders. Agios has just launched that product and revenue has leapt 138 percent, yet we pass. A negative forward earnings multiple and zero profit margins show this is still early revenue from one asset, not a durable business with proven economics.
The ethical screen raises no issues. Unknown competitive protection and a negative 33 percent return on equity leave it vulnerable once larger firms target the same cellular metabolism space.
Risks centre on clinical setbacks, ongoing cash burn and dilution before any sustained profits appear. The modest gap to fair value does not offset the binary nature of drug development. Analysis, not advice.
| Forward P/E | -9.4x |
| EPS, trailing | -6.31 |
| EPS, forward | -3.19 |
| Revenue growth | +330.0%growing very fast |
| Profit margin | -264.8%currently unprofitable |
| Return on equity | -32.9%not currently earning a positive return on equity |
| FCF yield | -14.79% |
| Debt to equity | 2.71heavy leverage: higher risk if revenue softens |
| Current ratio | 9.69comfortably covers its short-term bills |
| Beta | 0.62steadier than the market |
| Short interest, float | 0.11% |
| 52-week range | 22.24 - 46.00 |
| Market cap | $1.8B |
| Employees | 539 |
AGIO-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; as a biotechnology name, trial and regulatory outcomes can move it sharply either way; it carries a real debt load, which raises the stakes if revenue slips.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from distribution to markup since the last review.
The framework has shifted from markup to distribution since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Agios Pharmaceuticals (AGIO) Stock Looks Pricey Despite Its 39% Run Yahoo Finance · 14d ago
- Agios Pharmaceuticals Inc (AGIO) (Q3 2026) Earnings Call Highlights: Revenue Surges 4x on ... Yahoo Finance · 15d ago
- Agios Pharmaceuticals, Inc. Q3 2026 Earnings Call Summary Yahoo Finance · 16d ago
- What Agios Pharmaceuticals (AGIO) Said on Its Q3 Earnings Call Yahoo Finance · 16d ago
- Agios Pharmaceuticals (AGIO) Reports Q3 Loss, Beats Revenue Estimates Yahoo Finance · 16d ago
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-26 | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | 7,866 | $296,470 |
| 2026-10-21 | Gheuens Sarah | Chief Medical Officer | S - Sale+OE | 1,989 | $74,642 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Date | Politician | Party | Type | Amount |
|---|---|---|---|---|
| 2026-08-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2026-08-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2026-08-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2026-08-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| 2026-08-20 | Gil Cisneros | Democrat | buy | 1K–15K |
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $27.99 | +3.0% | · | $1,030 | +3.0% |
| 2 months | $32.92 | -12.5% | · | $876 | -12.5% |
| 3 months | $27.59 | +4.5% | · | $1,045 | +4.5% |
| 6 months | $27.46 | +5.0% | · | $1,050 | +5.0% |
| 1 year | $34.51 | -16.5% | · | $835 | -16.5% |
| 2 years | $47.22 | -39.0% | · | $610 | -39.0% |
| 3 years | $25.87 | +11.4% | · | $1,114 | +11.4% |
| 5 years | $57.74 | -50.1% | · | $499 | -50.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever AGIO does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.